CNTA News and Press, Centessa Pharmaceuticals plc From 03/30/23

2023-03-30 08:51:14 ET Centessa Pharmaceuticals press release ( NASDAQ: CNTA ): Q4 GAAP EPS of -$0.45 misses by $0.01 . Cash and Cash Equivalents: $393.6 million as of December 31, 2022, which the Company expects will fund operations into 2026, without drawing on ...

– Initiated registration program for SerpinPC to treat hemophilia B; Enrolling subjects in PRESent-5, observational study – – First subject dosed in Phase 1/2a clinical trial for LB101, a PD-L1xCD47 LockBody ® to treat solid tumors; Preclinical ...

Clarivate Announces Gordon Samson as President, Intellectual Property and Nominates Dr. Saurabh Saha as New Independent Director Canada NewsWire Naming the first of three business leaders for its newly created market segments and nominating new Independent Director to its Boar...

BOSTON and LONDON, March 01, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the appointment of Patrick Yue, MD, to Centessa’...

BOSTON and LONDON, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that the Company will present additional data from the open...

BOSTON and LONDON, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today announced that members of its management team will participat...

Centessa Pharma ( NASDAQ: CNTA ) said it had received clearance for Investigational New Drug application from the U.S. Food and Drug Administration to start a Phase 1/2a trial of LB101 for the treatment of solid tumors. LB101, monoclonal antibody targeting solid tumors, is the fir...

BOSTON and LONDON, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that it has received clearance of its Investigational N...

Oral presentation at American Society of Hematology (ASH) Annual Meeting highlights continued favorable safety and tolerability profile and sustained long-term efficacy results for SerpinPC: 93% reduction in median ABR for both all-bleeds and spontaneous joint bleeds in highest do...

BOSTON and LONDON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today announced Karen Anderson as its new Chief People Officer. In ...